section name header

Pronunciation

er-too-gli-FLOE-zin

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification: sodium-glucose co-transporter 2 (SGLT2) inhibitors

Indications

BEERS REMS


Action

  • Inhibits proximal renal tubular sodium-glucose cotransporter 2 (SGLT2), which reduces reabsorption of glucose and lowers renal threshold for glucose, ultimately increasing excretion of glucose in urine.
Therapeutic effects:
  • Improved glycemic control.

Pharmacokinetics

Absorption: Completely absorbed following oral administration.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Mostly metabolized by UDP-glucuronyl transferases (UGT) to inactive metabolites; minimal metabolism by CYP isoenzymes (12%). 41% excreted in feces (33.8% as unchanged drug); 50.2% excreted in urine (1.5% as unchanged drug).

Half-Life: 16.6 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown1 hr24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension

Endo: hypoglycemia ( with other medications)

F and E: dehydration, KETOACIDOSIS, polydipsia

GU: genital mycotic infection, acute kidney injury, NECROTIZING FASCIITIS OF PERINEUM (FOURNIER'S GANGRENE), polyuria, urinary tract infection (including pyelonephritis), UROSEPSIS, vaginal pruritus

Metab: hyperlipidemia, weight loss

MS: back pain, lower limb amputation (primarily toe and foot)

Neuro: dizziness, headache, syncope

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA)

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Steglatro